**Core tip:** This is a systematic review of the current literature reporting the surgical outcomes of liver resection for Barcelona Clinic Liver Cancer (BCLC) Stage B and C hepatocellular carcinomas (HCC). Based on this review, there is robust evidence that indications for primary surgical resection of HCC should be extended to include BCLC stage B lesions in selected patients. There is a need for further studies that stratify BCLC stage C lesions and potentially extend surgical indications for resectable lesions.

INTRODUCTION
============

Hepatocellular carcinoma (HCC) remains a significant disease burden worldwide today\[[@B1]\]. Appropriate treatment for HCC is complex because radical oncological clearance and preservation of adequate liver function need to be carefully balanced. Several staging systems have been developed to guide management of HCC\[[@B2]-[@B7]\].

Surgical resection for HCC within the "Milan Criteria" or Barcelona Clinic Liver Cancer (BCLC) stage A is the widely accepted standard of care\[[@B8]\]. However, surgical treatment for BCLC stage B (intermediate) or C (advanced) lesions remains controversial\[[@B4]-[@B7]\]. Presently, the European Association for the Study of Liver Disease (EASL) and the American Association for the Study of Liver Disease (AASLD) guidelines do not recommend surgical resection for these patients\[[@B4],[@B7],[@B9]\].

However, despite the recommendations from these two large reputable organizations, many international high-volume tertiary centers, especially centers in Asia, still routinely perform surgical resection for large solitary lesions, multifocal lesions and lesions with macrovascular invasion\[[@B10]-[@B16]\]. Critical appraisal of both Western and Asian literature is needed to resolve the controversies.

The aim of this study was to perform a systematic review and summarize the current literature to determine the long-term survival outcomes after curative resection of intermediate and advanced HCCs.

MATERIALS AND METHODS
=====================

A systematic review of the published literature was performed using the PubMed database from 1^st^ January 1999 to 31^st^ Dec 2014 to identify studies that reported outcomes of liver resection as the primary curative treatment for BCLC stage B or C HCC.

The primary end point was to determine the overall survival (OS) and disease free survival (DFS) of liver resection of HCC in BCLC stage B or C in patients with adequate liver reserve (*i.e*., Child's A or B status) and in good general status (PS 0-2). The secondary end points were to assess the morbidity and mortality of liver resection in large HCC (defined as lesions larger than 10 cm in diameter) and to compare the OS and DFS after surgical resection of solitary *vs* multifocal HCC.

The Medical Subject Heading (MeSH) major topic was "hepatocellular carcinoma". The keywords used were "liver tumor", "hepatoma", "liver neoplasm", "liver cancer", "Barcelona Clinic Liver Cancer", "multifocal" and "vascular invasion". The keywords used for surgical resection were "hepatectomy", "liver resection", "liver surgery", "partial hepatectomy", "hemi-hepatectomy", "sectionectomy", "segmentectomy", "non-anatomical resection", "anatomical resection", "curative surgery" and "surgical procedures". The keywords used for liver reserve were "Child A/B", "Child Pugh A/B", "early liver disease" and "early liver cirrhosis". Key references of the short-listed studies were also searched manually.

Two authors conducted the search independently, with the search results obtained by both authors discussed with the senior author Goh BK. The final list of studies to be short-listed was decided by consensus between all three authors. This study was conducted in accordance to the PRISMA guidelines\[[@B17]\].

Data extraction
---------------

All short-listed studies were assessed independently according to a modified Newcastle-Ottawa scale. The three main factors assessed were: (1) selection of the patients; (2) comparability of the study groups; and (3) outcome assessment. The scoring scale ranged from 0-9 and studies of score 6 or greater were considered high quality and included in this study. The following data was extracted from the included studies: first author, year of data collection, year of publication, country of origin, characteristics of study population, number of patients, clinico-pathological characteristics, OS and DFS.

Inclusion criteria
------------------

The inclusion criteria were: (1) studies reporting surgical resection of lesions fulfilling the criteria of BCLC stage B (intermediate) or BCLC stage C (advanced) HCC, studies reporting surgical resection for large HCC, multifocal HCC and HCC with vascular invasion; (2) evaluation of at least one of the clinico-pathological or survival characteristics mentioned in the "parameters and outcomes of interest" section below; and (3) for studies reported by the same institution (and/or) authors with overlapping cohorts, only the study with the larger sample size or the one with higher quality was included. Major resection was defined as resection of 3 segments or more whereas minor resection involved 2 segments or less\[[@B18]\].

Studies which described adjunctive treatments such as radiofrequency ablation (RFA), selective internal radiation therapy (SIRT), trans- arterial chemoembolization (TACE) and infusional chemotherapy were also included.

Exclusion criteria
------------------

All studies that did not meet the inclusion criteria were excluded. In addition, the following exclusion criteria were used: (1) studies that did not report the survival outcomes of surgically resected HCC; (2) studies that focused on transplant, RFA, TACE and SIRT; (3) studies that focused on DNA, biochemical and proteomic analysis of HCC; (4) studies that focused on radiological imaging techniques; (5) studies reporting patients with Child-Pugh grade C or unknown status; (6) studies reporting tumor rupture, extra-hepatic metastases and/or lymph node metastases; (7) studies which included palliative (R2) resections; and (8) studies written in languages other than English.

Definitions, parameters and outcomes of interest
------------------------------------------------

The most updated BCLC staging criteria was used as the reference staging system\[[@B4],[@B7],[@B9]\]. Adequate liver function was defined as Child-Pugh grade A or B. The main outcomes of interest were the OS and DFS. Clinico-pathological characteristics including age, gender, Child-Pugh status, hepatitis status, tumor size, number of nodules, extent of macrovascular invasion, extent of liver resection, post-operative morbidity, mortality and recurrent disease were recorded.

Statistical methods
-------------------

If the data on the OS or DFS was not provided explicitly in a study, the information was derived from the survival graphs if present, or calculated from the primary data using a measurement method as described by Lim et al\[[@B8]\]. The 1, 3 and 5 year OS and DFS were summarized graphically using bubble plots, with the sample size of each cohort relative to the size of the bubble.

The inverse variance (IV) method was used to pool the RR across studies. A fixed 0.5 zero-cell correction was used when the number of events for one of the groups was zero. Pairwise comparisons of subtypes were done. If there were no events in an outcome of interest for both groups that were compared, the study was excluded from the meta-analysis for the specific outcome.

Heterogeneity between the studies was evaluated using the chi-squared test of heterogeneity. A random effects model was used. Sensitivity analyses were performed by excluding each study individually from the pool of studies combined for each outcome. Pooled results from these subgroups were computed and compared with the pooled results from the set of studies without these exclusion criteria. All statistical analyses were conducted using SAS 9.3 (SAS Institute, Cary, NC, United States) and Review Manager 5 (Nordic Cochrane, Copenhagen, Denmark).

RESULTS
=======

The systematic review identified 1908 articles, from which 130 articles were selected for full text review. Seventy-four articles met the inclusion criteria and were analyzed in this systematic review\[[@B10]-[@B14],[@B19]-[@B87]\]. Fifty-six articles were excluded for the following reasons\[[@B88]-[@B143]\]: Three because they were not published in the English language\[[@B88]-[@B90]\], 11 because other treatment modalities were used as primary treatment\[[@B91]-[@B101]\], 19 because of overlapping cohorts\[[@B102]-[@B120]\], nine due to incomplete data\[[@B121]-[@B129]\], two due to inclusion of palliative liver resection\[[@B130]-[@B131]\], and 12 because the study populations included patients with other types of hepatic malignancies\[[@B132]-[@B143]\] (Supplementary Figure 1). Analysis of the resection outcomes of the included studies were grouped according to (1) BCLC stage B or C HCC; (2) Size of HCC; and (3) multifocal tumors.
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BCLC Stage B or C HCC
---------------------

Studies which classified HCC according to BCLC Staging System\[[@B4]-[@B7]\] utilized the following common definitions: Stage B - single tumor more than 5 cm in diameter; 2 to 3 tumors of which at least one is more than 3 cm in diameter; or more than 3 tumors of any diameter; Stage C - any tumor with radiologically evident and histologically proven macrovascular invasion, N1 disease or M1 disease.

The baseline characteristics of the patients are presented in Table [1](#T1){ref-type="table"}. There are 6103 BCLC stage B cases in 19 studies and 3449 BCLC stage C cases in 32 studies. The clinical outcomes are summarized in Table [2](#T2){ref-type="table"}. The study recruitment periods extended from 1982 to 2011. Figure [1](#F1){ref-type="fig"} are bubble plots showing OS and DFS, with bubble size indicating relative sample size. The median 5-year OS of BCLC stage B was 38.7% (range 10.0-57.0); while the median 5-year OS of BCLC stage C was 20.0% (range 0.0-42.0). The collective median 5-year OS of both stages was 27.9% (0.0-57.0).

###### 

Characteristics of patients classified as BCLC stage B or C hepatocellular carcinoma

  **Ref**.                                    **Year**   ***n***   **Male (%)**   **Cirrhosis (%)**   **HBV (%)**   **HCV (%)**   **Median tumor diameter (cm)**
  ------------------------------------------- ---------- --------- -------------- ------------------- ------------- ------------- --------------------------------
  BCLC stage B                                                                                                                    
  Régimbeau et al\[[@B25]\]                   1999       94        75 (79.8)      37 (39.4)           35 (37.2)     10 (10.6)     12.0
  Hanazaki et al\[[@B19]\]                    2001       133       105 (78.9)     NS                  NS            NS            8.6
  Ng et al\[[@B10]\]                          2005       380       278 (73.2)     380 (100.0)         281 (73.9)    20 (5.3)      NS
  Chen et al\[[@B26]\] (TP1)                  2006       959       816 (85.1)     717 (74.8)          776 (80.9)    NS            14.9
  Chen et al\[[@B26]\] (TP2)                  2006       1143      968 (84.7)     897 (78.5)          940 (82.2)    NS            11.1
  Cho et al\[[@B26]\]                         2007       230       46 (20.0)      35 (15.2)           40 (17.4)     5 (2.2)       7.1
  Vitale et al\[[@B31]\]                      2009       124       NS             NS                  NS            NS            NS
  Yang et al\[[@B11]\]                        2009       260       228 (87.7)     198 (76.2)          239 (91.9)    NS            9.6
  Zhou et al\[[@B29]\] (SX)                   2009       56        49 (87.5)      50 (89.3)           55 (98.2)     0 (0.0)       9.5
  Zhou et al\[[@B29]\] (TCSX)                 2009       52        48 (92.3)      49 (94.2)           51 (98.1)     0 (0.0)       9.0
  Delis et al\[[@B27]\]                       2010       66        45 (68.2)      NS                  36 (54.5)     15 (22.7)     8.4
  Lin et al\[[@B30]\]                         2010       93        75 (80.6)      NS                  60 (64.5)     22 (23.7)     8.0
  Ramacciato et al\[[@B28]\]                  2010       51        37 (72.5)      44 (86.3)           NS            NS            8.2
  Xu et al\[[@B21]\]                          2010       165       NS             NS                  NS            NS            NS
  Wei et al\[[@B22]\]                         2011       51        NS             NS                  NS            NS            NS
  Zhou et al\[[@B20]\]                        2011       85        74 (87.1)      65 (76.5)           68 (80.0)     6 (7.1)       NS
  Chang et al\[[@B32]\]                       2012       318       263 (82.7)     97 (30.5)           201 (63.2)    57 (17.9)     7.4
  Hsu et al\[[@B34]\]                         2012       268       213 (79.5)     NS                  176 (65.7)    48 (17.9)     NS
  Ma et al\[[@B23]\]                          2012       178       158 (88.8)     79 (44.4)           140 (78.7)    41 (23.0)     NS
  Torzilli et al\[[@B12]\]                    2013       737       586 (79.5)     360 (48.8)          158 (21.4)    208 (28.2)    6.0
  Zhong et al\[[@B120]\]                      2013       660       NS             NS                  NS            NS            NS
  BCLC Stage C                                                                                                                    
  Ohkubo et al\[[@B79]\]                      2000       47        41 (87.2)      NS                  20 (42.6)     11 (23.4)     NS
  Wu et al\[[@B57]\] (SX 1^st^ bifurcation)   2000       15        13 (86.7)      NS                  14 (93.3)     2 (13.3)      10.8
  Wu et al\[[@B57]\] (SX 1^st^)               2000       97        83 (85.6)      NS                  67 (69.1)     25 (25.8)     8.8
  Minagawa et al\[[@B58]\]                    2001       18        NS             NS                  NS            NS            5.3
  Poon et al\[[@B59]\]                        2003       20        18 (90.0)      NS                  17 (85.0)     NS            8.6
  Fan et al\[[@B60]\] (SX, CHT)               2005       84        76 (90.5)      NS                  NS            NS            10.5
  Fan et al\[[@B60]\] (SX)                    2005       24        20 (83.3)      NS                  NS            NS            NS
  Pawlik et al\[[@B10]\]                      2005       102       87 (85.3)      NS                  NS            NS            10
  Chen et al\[[@B62]\] (SX 1^st^)             2006       286       248 (86.7)     NS                  172 (60.1)    NS            7.7
  Chen et al\[[@B62]\] (SX Main)              2006       152       135 (88.8)     NS                  95 (62.5)     NS            8.1
  Ikai et al\[[@B64]\]                        2006       78        57 (73.1)      NS                  24 (30.8)     36 (46.2)     NS
  Le Treut et al\[[@B63]\]                    2006       26        22 (84.6)      NS                  NS            NS            9
  Kamiyama et al\[[@B66]\] (RTSX)             2007       15        13 (86.7)      NS                  NS            NS            6.47
  Kamiyama et al\[[@B66]\] (SX)               2007       28        25 (89.3)      NS                  NS            NS            11
  Takizawa et al\[[@B65]\]                    2007       12        8 (66.7)       NS                  NS            NS            8.24
  Ban et al\[[@B69]\]                         2009       45        NS             NS                  NS            NS            NS
  Inoue et al\[[@B70]\] (TB)                  2009       20        19 (95.0)      NS                  6 (30.0)      12 (60.0)     NS
  Inoue et al\[[@B70]\] (EN)                  2009       29        26 (89.7)      NS                  10 (34.5)     15 (51.7)     NS
  Kondo et al\[[@B68]\] (SX, Main)            2009       5         NS             NS                  NS            NS            NS
  Kondo et al\[[@B68]\] (SX, 1^st^-3^rd^)     2009       43        NS             NS                  NS            NS            NS
  Peng et al\[[@B67]\] (TC)                   2009       51        46 (90.2)      NS                  31 (60.8)     5 (9.8)       9.04
  Peng et al\[[@B67]\] (SX)                   2009       53        50 (94.3)      NS                  40 (75.5)     3 (5.7)       8.39
  Vitale et al\[[@B31]\]                      2009       48        NS             NS                  NS            NS            NS
  Shi et al\[[@B71]\]                         2010       406       361 (88.9)     NS                  354 (87.2)    3 (0.7)       NS
  Xu et al\[[@B21]\]                          2010       95        NS             NS                  NS            NS            NS
  Lin et al\[[@B72]\] (TP1)                   2011       21        NS             NS                  NS            NS            NS
  Lin et al\[[@B72]\] (TP2)                   2011       47        NS             NS                  NS            NS            NS
  Peng et al\[[@B14]\]                        2011       201       187 (93.0)     NS                  172 (85.6)    4 (2.0)       NS
  Wei et al\[[@B22]\]                         2011       17        NS             NS                  NS            NS            NS
  Chang et al\[[@B32]\]                       2012       160       140 (87.5)     60 (37.5)           112 (70.0)    20 (12.5)     7.5
  Huang et al\[[@B56]\] (SX)                  2012       54        40 (74.1)      NS                  41 (75.9)     2 (3.7)       21.4
  Huang et al\[[@B56]\] (SXTC)                2012       62        42 (67.7)      NS                  50 (80.6)     0 (0.0)       20.5
  Liu et al\[[@B74]\]                         2012       65        54 (83.1)      NS                  NS            NS            NS
  Ma et al\[[@B23]\]                          2012       46        41 (89.1)      25 (54.3)           41 (89.1)     0 (0.0)       NS
  Li et al\[[@B75]\]                          2013       13        11 (84.6)      NS                  NS            NS            10.2
  Nitta et al\[[@B77]\]                       2013       35        28 (80.0)      NS                  7 (20.0)      21 (60.0)     7
  Roayaie et al\[[@B78]\]                     2013       164       132 (80.5)     NS                  61 (37.2)     70 (42.7)     90
  Tang et al\[[@B76]\]                        2013       186       166 (89.2)     NS                  159 (85.5)    23 (12.4)     9.53
  Torzilli et al\[[@B12]\]                    2013       297       228 (76.8)     169 (56.9)          61 (20.5)     100 (33.7)    6.0
  Zhong et al\[[@B120]\]                      2013       248       NS             NS                  NS            NS            NS

TP: Time period; SX: Surgery; TC: Trans- arterial chemoembolization; CHT: Chemotherapy; TB: Thrombectomy; EN: *En.bloc*, RT: Radiotherapy.

###### 

Clinical outcomes of liver resection in BCLC stage B or C hepatocellular carcinoma

  **Ref**.                                    **Recruitment period**   ***n***   **Overall survival (%)**   **Median OS (mo)**   **Disease free survival (%)**   **Median DFS (mo)**                        
  ------------------------------------------- ------------------------ --------- -------------------------- -------------------- ------------------------------- --------------------- ------ ------ ------ ------
  BCLC stage B                                                                                                                                                                                              
  Régimbeau et al\[[@B25]\]                   1984-1996                94        69.0                       45.0                 31.0                            NS                    51.0   35.0   21.0   NS
  Hanazaki et al\[[@B19]\]                    1983-1997                133       70.0                       38.0                 28.0                            NS                    65.0   26.0   20.0   NS
  Ng et al\[[@B10]\]                          1982-2001                380       74.0                       50.0                 39.0                            36.9                  54.0   38.0   26.0   15.6
  Chen et al\[[@B26]\] (TP1)                  1990-2003                959       67.8                       50.7                 27.9                            16.0                  56.5   34.7   18.9   10.0
  Chen et al\[[@B26]\] (TP2)                  1990-2003                1143      71.2                       58.8                 38.7                            19.0                  61.5   38.6   23.8   17.0
  Cho et al\[[@B26]\]                         1998-2001                230       85.0                       59.3                 52.9                            NS                    58.3   40.0   31.7   NS
  Vitale et al\[[@B31]\]                      2000-2007                124       85.0                       56.0                 NS                              NS                    NS     NS     NS     NS
  Yang et al\[[@B11]\]                        1992-2002                260       87.0                       55.5                 38.2                            45.5                  82.4   51.0   35.0   36.7
  Zhou et al\[[@B29]\] (SX)                   2001-2003                56        69.6                       32.1                 21.1                            NS                    39.2   21.4   8.9    NS
  Zhou et al\[[@B29]\] (TCSX)                 2001-2003                52        73.1                       40.4                 30.7                            NS                    48.9   25.5   12.8   NS
  Delis et al\[[@B27]\]                       2002-2008                66        69.0                       37.0                 32.0                            36.0                  60.0   33.0   29.0   29.0
  Lin et al\[[@B30]\]                         2001-2007                93        83.0                       49.0                 30.0                            27.6                  NS     NS     NS     NS
  Ramacciato et al\[[@B28]\]                  2000-2006                51        NS                         NS                   56.1                            68.0                  NS     NS     41.3   NS
  Xu et al\[[@B21]\]                          1991-2004                165       75.6                       57.4                 40.2                            NS                    NS     NS     NS     NS
  Wei et al\[[@B22]\]                         2003-2007                51        84.3                       54.9                 NS                              NS                    70.2   45.4   NS     NS
  Zhou et al\[[@B20]\]                        1995-2002                85        93.8                       56.2                 47.0                            56.0                  74.3   34.4   14.8   36.0
  Chang et al\[[@B32]\]                       1991-2006                318       81.2                       59.4                 46.5                            NS                    55.8   39.4   31.9   6.0
  Hsu et al\[[@B34]\]                         2002-2010                268       82.0                       68.0                 46.0                            NS                    NS     NS     NS     NS
  Ma et al\[[@B23]\]                          1998-2011                178       77.0                       26.0                 10.0                            27.9                  49.0   18.0   NS     16.8
  Torzilli et al\[[@B12]\]                    1990-2009                737       88.0                       71.0                 57.0                            NS                    63.0   38.0   27.0   NS
  Zhong et al\[[@B120]\]                      2000-2007                660       91.0                       67.0                 44.0                            NS                    NS     NS     NS     NS
  BCLC stage C                                                                                                                                                                                              
  Ohkubo et al\[[@B79]\]                      1985-1997                47        53.9                       33.2                 23.9                            NS                    31.2   17.9   NS     NS
  Wu et al\[[@B57]\] (SX 1^st^ bifurcation)   1990-1998                15        80.0                       44.0                 26.4                            NS                    67.0   32.0   21.1   NS
  Wu et al\[[@B57]\] (SX 1^st^)               1990-1998                97        68.0                       34.0                 28.5                            NS                    51.0   22.0   20.4   NS
  Minagawa et al\[[@B58]\]                    1989-1998                18        82.0                       42.0                 42.0                            40.8                  NS     NS     NS     7.8
  Poon et al\[[@B59]\]                        1989-2000                20        30.0                       13.3                 13.3                            6.0                   15.0   5.0    5.0    2.9
  Fan et al\[[@B60]\] (SX, CHT)               1997-2002                84        29.3                       15.6                 NS                              15.1                  NS     NS     NS     NS
  Fan et al\[[@B60]\] (SX)                    1997-2002                24        22.7                       0.0                  NS                              10.1                  NS     NS     NS     NS
  Pawlik et al\[[@B10]\]                      1984-1999                102       45.0                       17.0                 10.0                            11.0                  NS     NS     NS     NS
  Chen et al\[[@B62]\] (SX 1^st^)             1990-2003                286       58.7                       22.7                 18.1                            18.8                  NS     NS     NS     NS
  Chen et al\[[@B62]\] (SX Main)              1990-2003                152       39.5                       5.7                  0.0                             10.1                  NS     NS     NS     NS
  Ikai et al\[[@B64]\]                        1990-2002                78        45.7                       21.7                 10.9                            8.9                   NS     NS     NS     NS
  Le Treut et al\[[@B63]\]                    1988-2004                26        38.5                       20.0                 13.0                            9.0                   NS     NS     NS     NS
  Kamiyama et al\[[@B66]\] (RTSX)             1990-2006                15        86.2                       43.5                 34.8                            19.6                  NS     NS     NS     NS
  Kamiyama et al\[[@B66]\] (SX)               1990-2006                28        39.0                       13.1                 13.1                            9.1                   NS     NS     NS     NS
  Takizawa et al\[[@B65]\]                    1992-2003                12        63.6                       53.0                 26.0                            26.0                  NS     NS     NS     NS
  Ban et al\[[@B69]\]                         1992-2008                45        69.6                       37.4                 22.4                            20.0                  30.4   21.2   0.0    NS
  Inoue et al\[[@B70]\] (TB)                  1995-2006                20        58.0                       46.0                 39.0                            NS                    34.0   34.0   23.0   NS
  Inoue et al\[[@B70]\] (EN)                  1995-2006                29        65.0                       41.0                 41.0                            NS                    38.0   22.0   18.0   NS
  Kondo et al\[[@B68]\] (SX, Main)            1996-2004                5         20.0                       NS                   NS                              NS                    NS     NS     NS     NS
  Kondo et al\[[@B68]\] (SX, 1^st^-3^rd^)     1996-2004                43        54.0                       33.0                 27.0                            NS                    NS     NS     NS     NS
  Peng et al\[[@B67]\] (TC)                   1996-2004                51        50.9                       33.8                 21.6                            13.0                  NS     NS     NS     NS
  Peng et al\[[@B67]\] (SX)                   1996-2004                53        33.3                       17.0                 8.5                             9.0                   NS     NS     NS     NS
  Vitale et al\[[@B31]\]                      2000-2007                48        55.0                       44.0                 0.0                             NS                    NS     NS     NS     NS
  Shi et al\[[@B71]\]                         2001-2003                406       34.4                       13.0                 NS                              NS                    13.3   4.7    NS     NS
  Xu et al\[[@B21]\]                          1991-2004                95        37.5                       18.2                 14.2                            NS                    NS     NS     NS     NS
  Lin et al\[[@B72]\] (TP1)                   1996-2006                21        77.0                       19.0                 5.0                             21.0                  NS     NS     NS     NS
  Lin et al\[[@B72]\] (TP2)                   1996-2006                47        76.0                       51.0                 36.0                            36.0                  NS     NS     NS     NS
  Peng et al\[[@B14]\]                        2002-2007                201       42.0                       14.1                 11.1                            20.0                  NS     NS     NS     NS
  Wei et al\[[@B22]\]                         2003-2007                17        52.9                       29.4                 NS                              NS                    35.2   17.6   NS     NS
  Chang et al\[[@B32]\]                       1990-2009                34        45.0                       20.0                 20.0                            NS                    NS     NS     NS     NS
  Huang et al\[[@B56]\] (SX)                  1991-2006                160       57.6                       33.8                 29.1                            NS                    35.3   27.2   25.0   NS
  Huang et al\[[@B56]\] (SXTC)                1998-2008                54        71.0                       35.0                 11.0                            NS                    NS     NS     NS     NS
  Liu et al\[[@B74]\]                         1998-2008                62        71.0                       24.0                 6.0                             NS                    NS     NS     NS     NS
  Ma et al\[[@B23]\]                          2000-2009                65        84.0                       NS                   NS                              17                    79.0   NS     NS     14.0
  Li et al\[[@B75]\]                          1998-2011                46        37.0                       16.0                 NS                              16.9                  16.0   NS     NS     7.7
  Nitta et al\[[@B77]\]                       1997-2009                13        53.8                       15.4                 NS                              NS                    NS     NS     NS     NS
  Roayaie et al\[[@B78]\]                     2006-2008                35        78.0                       37.4                 32.7                            NS                    45.0   11.8   11.8   NS
  Tang et al\[[@B76]\]                        1992-2010                164       50.0                       23.0                 14                              13.1                  40.0   20.0   18.0   8.1
  Torzilli et al\[[@B12]\]                    2006-2008                186       40.1                       13.6                 NS                              10.0                  NS     NS     NS     NS
  Zhong et al\[[@B120]\]                      1990-2009                297       76.0                       49.0                 38.0                            NS                    46.0   28.0   18.0   NS
  Ohkubo et al\[[@B79]\]                      2000-2007                248       81.0                       46.0                 20.0                            NS                    NS     NS     NS     NS

TP: Time period; SX: Surgery; TC: Trans- arterial chemoembolization; CHT: Chemotherapy; TB: Thrombectomy; EN: *En.bloc*, RT: Radiotherapy.

Size of HCC
-----------

HCC analyzed according to size criterion were categorized as: Large HCC - greater than or equal to 10 cm in diameter; and Small HCC - less than 10 cm in diameter.

The baseline characteristics are presented in Table [3](#T3){ref-type="table"}. There are 2437 cases of large HCC in 21 studies and 5436 cases of small HCC in 14 studies. The clinical outcomes are summarized in Table [4](#T4){ref-type="table"}. The study recruitment periods extended from 1964 to 2011. Supplementary Figure 2A and B are forest plots showing the morbidity and mortality respectively of the included studies. The pooled RR for morbidity \[RR (95%CI): 1.00 (0.76-1.31)\] and mortality \[RR (95%CI): 1.15 (0.73-1.80)\] were not significant. The median 5-year OS of large HCC was 33.0 % (range: 16.7-79.0) and the median 5-year OS of small HCC was 52.3% (range 21.0-89.2).

###### 

Characteristics of patients classified as large or small hepatocellular carcinoma

  **Ref**.                    **Year**   ***n***   **Male (%)**   **Cirrhosis (%)**   **HBV (%)**   **HCV (%)**   **Median tumor diameter (cm)**
  --------------------------- ---------- --------- -------------- ------------------- ------------- ------------- --------------------------------
  Large HCC                                                                                                       
  Poon et al\[[@B36]\]        2002       120       99 (82.5)      32 (26.7)           103 (85.8)    NS            13.8
  Yeh et al\[[@B38]\]         2003       211       164 (77.7)     63 (29.9)           163 (77.3)    16 (7.6)      13.9
  Zhou et al\[[@B37]\]        2003       621       NS             NS                  NS            NS            NS
  Liau et al\[[@B41]\]        2005       82        48 (58.5)      8 (9.8)             NS            NS            14.7
  Nagano et al\[[@B40]\]      2005       26        19 (73.1)      5 (19.2)            14 (53.8)     3 (11.5)      14.8
  Pawlik et al\[[@B10]\]      2005       300       222 (74.0)     NS                  188 (62.7)    NS            NS
  Lee et al\[[@B43]\]         2007       100       77 (77.0)      NS                  NS            NS            12.5
  Pandey et al\[[@B44]\]      2007       166       143 (86.1)     80 (48.2)           130 (78.3)    2 (1.2)       13.0
  Shah et al\[[@B42]\]        2007       24        NS             NS                  9 (37.5)      1 (4.2)       13.1
  Young et al\[[@B45]\]       2007       42        29 (69.0)      2 (4.8)             NS            NS            14.0
  Shimada et al\[[@B46]\]     2008       85        72 (84.7)      NS                  27 (31.8)     19 (22.4)     12.0
  Taniai et al\[[@B47]\]      2008       29        26 (89.7)      12 (41.4)           6 (20.7)      17 (58.6)     13.5
  Choi et al\[[@B50]\]        2009       50        34 (68.0)      13 (26.0)           33 (66.0)     1 (2.0)       NS
  Miyoshi et al\[[@B49]\]     2009       22        19 (86.4)      5 (22.7)            NS            NS            12.0
  Ng et al\[[@B48]\]          2009       44        33 (75.0)      NS                  15 (34.1)     3 (6.8)       12.4
  Yamashita et al\[[@B51]\]   2011       53        48 (90.6)      NS                  18 (34.0)     22 (41.5)     13.2
  Truant et al\[[@B35]\]      2012       52        38 (73.1)      23 (44.2)           6 (11.5)      NS            14.0
  Allemann et al\[[@B55]\]    2013       22        NS             9 (40.9)            4 (18.2)      2 (9.1)       13.5
  Ariizumi et al\[[@B54]\]    2013       107       NS             NS                  NS            NS            NS
  Shrager et al\[[@B52]\]     2013       130       98 (75.4)      NS                  56 (43.1)     23 (17.7)     14.2
  Yang et al\[[@B53]\]        2013       258       212 (82.2)     171 (66.3)          195 (75.6)    NS            13.2
  Small HCC                                                                                                       
  Miyoshi et al\[[@B49]\]     2009       230       160 (69.6)     114 (49.6)          NS            NS            3.4
  Allemann et al\[[@B55]\]    2013       79        NS             61 (77.2)           10 (12.7)     13 (16.5)     4.9
  Poon et al\[[@B36]\]        2002       368       295 (80.2)     203 (55.2)          311 (84.5)    NS            5.4
  Yeh et al\[[@B38]\]         2003       778       776 (99.7)     591 (76.0)          616 (79.2)    305 (39.2)    4.5
  Zhou et al\[[@B37]\]        2003       2039      NS             NS                  NS            NS            NS
  Liau et al\[[@B41]\]        2005       111       80 (72.1)      40 (36.0)           NS            NS            6.1
  Nagano et al\[[@B40]\]      2005       143       112 (78.3)     81 (56.6)           17 (11.9)     87 (60.8)     3.3
  Shah et al\[[@B42]\]        2007       165       NS             NS                  73 (44.2)     36 (21.8)     4.7
  Young et al\[[@B45]\]       2007       43        30 (69.8)      10 (23.3)           NS            NS            5.0
  Taniai et al\[[@B47]\]      2008       291       225 (77.3)     156 (53.6)          135 (46.4)    78 (26.8)     3.7
  Choi et al\[[@B50]\]        2009       447       344 (77.0)     244 (54.6)          331 (74.0)    26 (5.8)      NS
  Yamashita et al\[[@B51]\]   2011       412       328 (79.6)     NS                  60 (14.6)     311 (75.5)    3.8
  Truant et al\[[@B35]\]      2012       37        28 (75.7)      26 (70.3)           1 (2.7)       NS            4.7
  Yang et al\[[@B53]\]        2013       293       236 (80.5)     201 (68.6)          216 (73.7)    NS            6.7

HCC: Hepatocellular carcinoma.

###### 

Clinical outcomes of liver resection in large or small hepatocellular carcinoma

  **Ref**.                       **Recruitment period**   ***n***   **Overall survival (%)**   **Median OS (mo)**   **Disease free survival (%)**   **Median DFS (mo)**                        
  ------------------------------ ------------------------ --------- -------------------------- -------------------- ------------------------------- --------------------- ------ ------ ------ ------
  Large HCC                                                                                                                                                                                    
  Poon et al\[[@B36]\]           1991-2000                120       60.6                       37.8                 27.5                            18.8                  32.0   14.1   9.5    5.5
  Yeh et al\[[@B38]\]            1982-2001                211       48.1                       24.0                 16.7                            NS                    32.9   18.8   12.7   NS
  Zhou et al\[[@B37]\]           1964-1999                621       68.0                       37.3                 26.2                            NS                    NS     NS     NS     NS
  Liau et al\[[@B41]\]           1985-2002                82        73.0                       49.0                 33.0                            32.0                  80.0   44.0   24.0   22.0
  Nagano et al\[[@B40]\]         1985-2001                26        41.0                       29.3                 29.3                            10.1                  65.4   49.0   NS     29.0
  Pawlik et al\[[@B10]\]         1981-2000                300       64.9                       36.7                 26.9                            20.3                  NS     NS     NS     NS
  Lee et al\[[@B43]\]            1997-2003                100       66.0                       44.0                 31.0                            NS                    43.0   26.0   20.0   NS
  Pandey et al\[[@B44]\]         1995-2006                166       65.0                       35.0                 28.6                            20.0                  NS     NS     NS     NS
  Shah et al\[[@B42]\]           1993-2004                24        69.0                       63.0                 54.0                            NS                    41.0   23.0   NS     8.4
  Young et al\[[@B45]\]          1994-2006                42        70.0                       45.0                 45.0                            NS                    62.0   49.0   43.0   NS
  Shimada et al\[[@B46]\]        1988-2004                85        NS                         NS                   31.5                            NS                    NS     NS     NS     NS
  Taniai et al\[[@B47]\]         1987-2006                29        51.9                       33.6                 33.6                            NS                    48.4   21.5   21.5   NS
  Choi et al\[[@B50]\]           1996-2006                50        70.0                       50.2                 40.2                            NS                    49.0   38.6   38.6   9.0
  Miyoshi et al\[[@B49]\]        1987-2004                22        71.8                       60.3                 45.2                            20.5                  53.3   29.1   18.2   12.0
  Ng et al\[[@B48]\]             1990-2008                44        66.4                       38.1                 27.8                            21.5                  49.6   23.9   19.1   10.7
  Yamashita et al\[[@B51]\]      1995-2007                53        74.0                       43.0                 35.0                            NS                    50.0   40.0   24.0   NS
  Truant et al\[[@B35]\]         2000-2010                52        NS                         NS                   43.3                            NS                    NS     NS     39.3   NS
  Allemann et al\[[@B55]\]       1997-2009                22        84.0                       72.0                 45.0                            27.0                  64.0   28.0   27.0   10.0
  Ariizumi et al\[[@B54]\] (S)   1990-2008                NS        81.0                       60.0                 47.0                            14.3                  41.0   18.0   12.0   NS
  Ariizumi et al\[[@B54]\] (M)   1990-2008                NS        88.0                       83.0                 79.0                            38.5                  76.0   54.0   48.0   NS
  Shrager et al\[[@B52]\]        1992-2010                130       56.9                       30.2                 18.8                            17.0                  31.8   13.4   11.5   6.7
  Yang et al\[[@B53]\]           2002-2011                258       84.0                       62.0                 33.0                            NS                    61.0   24.0   6.0    NS
  Small HCC                                                                                                                                                                                    
  Miyoshi et al\[[@B49]\]        1987-2004                230       89.3                       74.6                 60.4                            48.2                  68.0   43.7   26.7   20.0
  Allemann et al\[[@B55]\]       1997-2009                79        75.0                       42.0                 21.0                            24.0                  50.0   18.0   14.0   15.0
  Poon et al\[[@B36]\]           1991-2000                368       83.3                       64.2                 51.6                            62.8                  64.6   41.8   28.2   25.4
  Yeh et al\[[@B38]\]            1982-2001                778       81.4                       57.3                 39.5                            NS                    61.2   40.7   32.1   NS
  Zhou et al\[[@B37]\]           1964-1999                2039      85.0                       65.1                 54.3                            NS                    NS     NS     NS     NS
  Liau et al\[[@B41]\]           1985-2002                111       80.0                       58.0                 39.0                            40.0                  70.0   49.0   31.0   28.0
  Nagano et al\[[@B40]\]         1985-2001                143       93.1                       74.5                 44.7                            53.4                  80.0   46.5   31.0   33.9
  Shah et al\[[@B42]\]           1993-2004                165       88.0                       70.0                 53.0                            NS                    76.0   53.0   43.0   38.0
  Young et al\[[@B45]\]          1994-2006                43        82.0                       63.0                 57.0                            NS                    71.0   54.0   48.0   NS
  Taniai et al\[[@B47]\]         1987-2006                291       81.0                       61.4                 45.0                            NS                    74.6   37.1   25.4   NS
  Choi et al\[[@B50]\]           1996-2006                447       91.3                       77.2                 65.9                            NS                    72.7   53.1   45.4   35.0
  Yamashita et al\[[@B51]\]      1995-2007                412       89.0                       67.0                 54.0                            NS                    72.0   45.0   37.0   NS
  Truant et al\[[@B35]\]         2000-2010                37        NS                         NS                   89.2                            NS                    NS     NS     60.7   NS
  Yang et al\[[@B53]\]           2002-2011                293       83.0                       66.0                 39.0                            NS                    56.0   26.0   9.0    NS

HCC: Hepatocellular carcinoma; M: Multi nodules; S: Single nodule.

Multifocal HCC
--------------

The baseline characteristics are presented in Supplementary Table [1](#T1){ref-type="table"}. There are 1095 cases in 9 studies. The clinical outcomes are summarized in Supplementary Table [2](#T2){ref-type="table"}. The study recruitment periods extended from 1992 to 2011. Supplementary Figure 3 displays the bubble plot showing overall and disease free survival rate of the included studies, with bubble size indicating relative sample size. The median 5-year OS was 54.0% (29.9-75.5). Supplementary Figure 4 was plotted to show 5 year OS for those studies with sample size greater or equal to 100 against the midpoint of recruitment period. The trend line was fitted using weighted least squares regression with sample size as weight. An uptrend with weighted slope 0.38 was seen in the plot.

DISCUSSION
==========

BCLC stage B or C HCC
---------------------

Presently, a major controversy in the management of HCC is the role of surgical resection for intermediate (BCLC stage B) and advanced (BCLC stage C) stage HCC. According to EASL and the AASLD guidelines, surgical resection is not offered for BCLC stages B and C HCC because of the poor 5-year overall survival rates\[[@B7],[@B9]\].

However, the results of this systematic review demonstrate that the median 5 year OS after surgical resection for BCLC B is 38.9% (range: 10.0%-57.0%). These outcomes are clearly not attainable by other modalities such as TACE which only confers a 40% two year survival and median survival of 20 mo for similar lesions\[[@B144]\].

This systematic review demonstrates that for BCLC C lesions, surgical resection results in uniformly poor results with a median 5-year OS of 20% (range: 0%-42.0%). However, proponents of resection argue that the tumor thrombus has the potential to cause portal vein obstruction, intractable ascites, esophageal variceal bleeding and liver failure\[[@B66]-[@B68]\]. This frequently leads to an even more rapid demise of these patients.

In general, the prognosis for tumor thrombus located within the main trunk has been reported to be poorer as compared to more distal lesions\[[@B58],[@B62],[@B68]\]. Some authors have advocated for portal vein resection for 1st order portal vein tumor thrombus with minimal bifurcation involvement, citing results of 5-year OS over 20% which was superior to thrombectomy alone\[[@B53],[@B75]\]. However, statistical analysis could not be performed due lack of stratification based on the extent of PV invasion, heterogeneous surgical procedures and different extents of hepatic vein and inferior vena cava involvement.

Size of HCC
-----------

The median 5 year OS in these large lesions was 33% (range: 16.7%-79.0%). The 10 cm arbitrary cut-off used by many studies represents the more advanced cases in the spectrum of BCLC B HCC\[[@B32]-[@B43]\]. In addition, BCLC C lesions that were \> 10 cm, usually with worse prognosis, were not excluded from the analysis in these studies, confounding the results. Despite this, the relatively favorable survival still indicates that surgical resection is beneficial for selected lesions within the combined spectrum of large HCCs\[[@B32]-[@B43]\].

Multifocal HCC
--------------

The EASL guidelines do not recommend surgical resection as first line therapy for all multifocal lesions\[[@B4],[@B7],[@B9]\]. On the other end of the spectrum, the APASL guidelines support resection of all lesions regardless of multifocality\[[@B2]\]. The APASL guidelines are supported by the fact that that over 65% OS has been reported after surgical resection for multifocal HCC within the "Milan criteria"\[[@B8]\]. In addition, studies from large specialized liver centers have showed favorable 5-year OS of over 50% after surgical resection for multifocal HCC\[[@B13],[@B77],[@B82]\]. This was further improved to between 55%-75% 5-year OS when performed in combination with RFA for bilobar lesions\[[@B76],[@B78],[@B80]\]. In this review, the median 5-year OS for all surgically resected multifocal HCC analyzed in this systematic review is 54.0% (range: 29.9%-75.5%), supporting surgical resection as the primary management of multifocal HCC.

It is important to highlight that surgical series of the aforementioned groups represent the entire spectrum of tumors beyond the "Milan criteria", and the wide range of survival reported for these lesions can be attributed to the heterogeneity of tumors encompassing large solitary and multifocal lesions of various sizes. Differentiation of the outcomes of purely single or multifocal HCC within this heterogeneous selection and is often not pursued in many studies and making interpretation of the data difficult.

Based on this review, it is evident that arbitrary classifications by the current guidelines do not adequately measure the extent of tumor burden, or prognosticate the continuum of outcomes after resection in the wide spectrum of tumors beyond the "Milan criteria". The "up-to-seven" criteria described by Mazzaferro et al\[[@B145]\] which is a better surrogate measure of tumor burden, could be useful for selection of patients with appropriately sized large solitary HCC or multifocal HCC with an acceptable number of lesions to undergo surgery\[[@B145],[@B146]\].

As evidenced by the results of this systematic review, long-term survival results after surgical resection are acceptable and represent the best possible therapeutic option for selected BCLC stage B HCC. This review showed that resection beyond criteria advised by the AASLD and EASL guidelines, has achieved survival exceeding that accorded by non-curative methods such as TACE and sorafenib which typically confers a median OS between 8-12 mo\[[@B147]-[@B152]\].

There are several limitations of this systematic review. Firstly, the studies in this review comprise a group of highly selected patients who underwent surgical resection. They do not represent the entire spectrum of patients with BCLC stage B or C HCC and will be biased towards patients who are more suitable surgical candidates. Secondly, there exists a myriad of neo-adjuvant and adjuvant treatment protocols included in these studies. However, the evidence does not show definitive benefit in terms of survival and thus the effect is not likely to be significant\[[@B153]-[@B155]\].

In conclusion, the results of the current systematic review provides evidence that indications for surgical resection of HCC should be extended to include selected BCLC stage B lesions and further studies should seek to identify the optimal criteria for the consideration of the criteria for liver resection.

ARTICLE HIGHLIGHTS
==================

Research background
-------------------

Hepatocellular carcinoma (HCC) remains a significant disease burden worldwide today. Appropriate treatment for HCC is complex because radical oncological clearance and preservation of adequate liver function need to be carefully balanced. Several staging systems have been developed to guide management of HCC.

Research motivation
-------------------

Surgical resection for HCC within the "Milan Criteria" or Barcelona Clinic Liver Cancer (BCLC) stage A is the widely accepted standard of care. However, surgical treatment for BCLC stage B (intermediate) or C (advanced) lesions remains controversial. Presently, the European Association for the Study of Liver Disease (EASL) and the American Association for the Study of Liver Disease (AASLD) guidelines do not recommend surgical resection for these patients. However, despite the recommendations from these two large reputable organizations, many international high-volume tertiary centers, especially centers in Asia, still routinely perform surgical resection for large solitary lesions, multifocal lesions and lesions with macrovascular invasion. Critical appraisal of both Western and Asian literature is needed to resolve the controversies.

Research objectives
-------------------

The aim of this study was to perform a systematic review and summarize the current literature to determine the long-term survival outcomes after curative resection of intermediate and advanced HCCs.

Research methods
----------------

We conducted a systematic review of the published literature using the PubMed database from 1^st^ January 1999 to 31^st^ Dec 2014 to identify studies that reported outcomes of liver resection as the primary curative treatment for BCLC stage B or C HCC. The primary end point was to determine the overall survival (OS) and disease free survival (DFS) of liver resection of HCC in BCLC stage B or C in patients with adequate liver reserve (*i.e*., Child's A or B status) and in good general status (PS 0-2). The secondary end points were to assess the morbidity and mortality of liver resection in large HCC (defined as lesions larger than 10 cm in diameter) and to compare the OS and DFS after surgical resection of solitary *vs* multifocal HCC.

Research results
----------------

We included a total of 74 articles in this systematic review. Analysis of the resection outcomes of the included studies were grouped according to: (1) BCLC stage B or C HCC; (2) Size of HCC; and (3) multifocal tumors. The median 5-year OS of BCLC stage B was 38.7% (range 10.0-57.0); while the median 5-year OS of BCLC stage C was 20.0% (range 0.0-42.0). The collective median 5-year OS of both stages was 27.9% (0.0-57.0). In examining the morbidity and mortality following liver resection in large HCC, the pooled RR for morbidity \[RR (95%CI): 1.00 (0.76-1.31)\] and mortality \[RR (95%CI): 1.15 (0.73-1.80)\] were not significant. Within the spectrum of BCLC B and C lesions, tumors greater than 10 cm were reported to have median 5-year OS of 33.0% and multifocal lesions 54.0%.

Research conclusions
--------------------

In conclusion, the results of the current systematic review provides evidence that indications for surgical resection of HCC should be extended to include selected BCLC stage B lesions and further studies should seek to identify the optimal criteria for the consideration of the criteria for liver resection.

Research perspectives
---------------------

As evidenced by the results of this systematic review, long-term survival results after surgical resection are acceptable and represent the best possible therapeutic option for selected BCLC stage B HCC. This review showed that resection beyond criteria advised by the AASLD and EASL guidelines, has achieved survival exceeding that accorded by non-curative methods such as TACE and sorafenib which typically confers a median OS between 8-12 mo. Further studies should seek to identify the optimal criteria for the consideration of the criteria for liver resection.
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